Article

Key clinical point: A de-escalated zoledronate schedule (≤6 infusions) did not affect breast cancer (BC)-specific survival outcomes in patients with hormone receptor-positive early BC.

Major finding: After a median follow-up of 96 months, the rates of disease-free survival were similar between patients who received ≤6 and ≥7 infusions (stratified hazard ratio 0.88; log-rank P = .64); however, there was an increase in adverse events, particularly arthralgia (P = .012) and nausea (P = .017), among patients who received ≥7 vs ≤6 infusions.

Study details: Findings are a substudy of the ABCSG-12 trial including 725 premenopausal women with early BC who were randomly assigned to receive hormone therapy (tamoxifen or anastrozole with goserelin) with or without zoledronic acid.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Beltran-Bless AA et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2022;180:108-116 (Dec 31). Doi: 10.1016/j.ejca.2022.12.003

Key clinical point: A de-escalated zoledronate schedule (≤6 infusions) did not affect breast cancer (BC)-specific survival outcomes in patients with hormone receptor-positive early BC.

Major finding: After a median follow-up of 96 months, the rates of disease-free survival were similar between patients who received ≤6 and ≥7 infusions (stratified hazard ratio 0.88; log-rank P = .64); however, there was an increase in adverse events, particularly arthralgia (P = .012) and nausea (P = .017), among patients who received ≥7 vs ≤6 infusions.

Study details: Findings are a substudy of the ABCSG-12 trial including 725 premenopausal women with early BC who were randomly assigned to receive hormone therapy (tamoxifen or anastrozole with goserelin) with or without zoledronic acid.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Beltran-Bless AA et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2022;180:108-116 (Dec 31). Doi: 10.1016/j.ejca.2022.12.003

Key clinical point: A de-escalated zoledronate schedule (≤6 infusions) did not affect breast cancer (BC)-specific survival outcomes in patients with hormone receptor-positive early BC.

Major finding: After a median follow-up of 96 months, the rates of disease-free survival were similar between patients who received ≤6 and ≥7 infusions (stratified hazard ratio 0.88; log-rank P = .64); however, there was an increase in adverse events, particularly arthralgia (P = .012) and nausea (P = .017), among patients who received ≥7 vs ≤6 infusions.

Study details: Findings are a substudy of the ABCSG-12 trial including 725 premenopausal women with early BC who were randomly assigned to receive hormone therapy (tamoxifen or anastrozole with goserelin) with or without zoledronic acid.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Beltran-Bless AA et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2022;180:108-116 (Dec 31). Doi: 10.1016/j.ejca.2022.12.003

Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P  =  .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).

Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.

Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.

Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065

Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P  =  .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).

Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.

Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.

Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065

Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P  =  .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).

Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.

Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.

Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065

Key clinical point: A first-line chemotherapy-free treatment regimen containing endocrine therapy (ET) and human epidermal growth factor receptor 2 (ERBB2)-targeted therapy led to excellent survival outcomes in patients with hormone receptor-positive (HR+) and ERBB2-positive (ERBB2+) metastatic breast cancer (BC).

Major finding: No significant difference was observed in overall survival (hazard ratio [HR] 1.03; P = .80) or progression-free survival (HR 1.00; P > .99) between patients receiving ERBB2-targeted therapy and chemotherapy with or without ET and patients receiving ERBB2-targeted therapy with ET only, regardless of the type of ERBB2-targeted therapy.

Study details: Findings are from a cohort study including 1723 patients with HR+/ERBB2+ metastatic BC who received ERBB2-targeted therapy and chemotherapy with or without ET (n = 1520) or ERBB2-targeted therapy with ET only (n = 203).

Disclosures: This study was supported by Unicancer. The authors declared receiving personal fees, research funding, grants, or travel expenses from several pharmaceutical companies.

Source: Carausu M et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes. JAMA Netw Open. 2022;5(12):e2247154 (Dec 15). Doi: 10.1001/jamanetworkopen.2022.47154

Key clinical point: A first-line chemotherapy-free treatment regimen containing endocrine therapy (ET) and human epidermal growth factor receptor 2 (ERBB2)-targeted therapy led to excellent survival outcomes in patients with hormone receptor-positive (HR+) and ERBB2-positive (ERBB2+) metastatic breast cancer (BC).

Major finding: No significant difference was observed in overall survival (hazard ratio [HR] 1.03; P = .80) or progression-free survival (HR 1.00; P > .99) between patients receiving ERBB2-targeted therapy and chemotherapy with or without ET and patients receiving ERBB2-targeted therapy with ET only, regardless of the type of ERBB2-targeted therapy.

Study details: Findings are from a cohort study including 1723 patients with HR+/ERBB2+ metastatic BC who received ERBB2-targeted therapy and chemotherapy with or without ET (n = 1520) or ERBB2-targeted therapy with ET only (n = 203).

Disclosures: This study was supported by Unicancer. The authors declared receiving personal fees, research funding, grants, or travel expenses from several pharmaceutical companies.

Source: Carausu M et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes. JAMA Netw Open. 2022;5(12):e2247154 (Dec 15). Doi: 10.1001/jamanetworkopen.2022.47154

Key clinical point: A first-line chemotherapy-free treatment regimen containing endocrine therapy (ET) and human epidermal growth factor receptor 2 (ERBB2)-targeted therapy led to excellent survival outcomes in patients with hormone receptor-positive (HR+) and ERBB2-positive (ERBB2+) metastatic breast cancer (BC).

Major finding: No significant difference was observed in overall survival (hazard ratio [HR] 1.03; P = .80) or progression-free survival (HR 1.00; P > .99) between patients receiving ERBB2-targeted therapy and chemotherapy with or without ET and patients receiving ERBB2-targeted therapy with ET only, regardless of the type of ERBB2-targeted therapy.

Study details: Findings are from a cohort study including 1723 patients with HR+/ERBB2+ metastatic BC who received ERBB2-targeted therapy and chemotherapy with or without ET (n = 1520) or ERBB2-targeted therapy with ET only (n = 203).

Disclosures: This study was supported by Unicancer. The authors declared receiving personal fees, research funding, grants, or travel expenses from several pharmaceutical companies.

Source: Carausu M et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes. JAMA Netw Open. 2022;5(12):e2247154 (Dec 15). Doi: 10.1001/jamanetworkopen.2022.47154

Key clinical point: The majority of topical and systemic therapies for atopic dermatitis (AD) effectively reduced pruritus, the most common patient-reported symptom.

Major finding: Topical and systemic treatments led to a mean reduction of 3.32 (99% CI 2.32-4.33) and 3.07 (99% CI 2.58-3.56) points in pruritus score, respectively. Wet-wrap therapy using halometasone (−4.75 points) was the most effective topical treatment, and 30 mg upadacitinib (−4.90 points) was the most effective systemic treatment.

Study details: This study analyzed 22 studies that included patients aged ≥ 10 years with AD who received topical or systemic treatments.

Disclosures: No information on the source of funding was provided. Two authors reported ties with various organizations.

Source: Rodriguez-Le Roy Y et al. Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. Front Med (Lausanne). 2022;9:1079323 (Dec 22). Doi: 10.3389/fmed.2022.1079323

Key clinical point: The majority of topical and systemic therapies for atopic dermatitis (AD) effectively reduced pruritus, the most common patient-reported symptom.

Major finding: Topical and systemic treatments led to a mean reduction of 3.32 (99% CI 2.32-4.33) and 3.07 (99% CI 2.58-3.56) points in pruritus score, respectively. Wet-wrap therapy using halometasone (−4.75 points) was the most effective topical treatment, and 30 mg upadacitinib (−4.90 points) was the most effective systemic treatment.

Study details: This study analyzed 22 studies that included patients aged ≥ 10 years with AD who received topical or systemic treatments.

Disclosures: No information on the source of funding was provided. Two authors reported ties with various organizations.

Source: Rodriguez-Le Roy Y et al. Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. Front Med (Lausanne). 2022;9:1079323 (Dec 22). Doi: 10.3389/fmed.2022.1079323

Key clinical point: The majority of topical and systemic therapies for atopic dermatitis (AD) effectively reduced pruritus, the most common patient-reported symptom.

Major finding: Topical and systemic treatments led to a mean reduction of 3.32 (99% CI 2.32-4.33) and 3.07 (99% CI 2.58-3.56) points in pruritus score, respectively. Wet-wrap therapy using halometasone (−4.75 points) was the most effective topical treatment, and 30 mg upadacitinib (−4.90 points) was the most effective systemic treatment.

Study details: This study analyzed 22 studies that included patients aged ≥ 10 years with AD who received topical or systemic treatments.

Disclosures: No information on the source of funding was provided. Two authors reported ties with various organizations.

Source: Rodriguez-Le Roy Y et al. Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. Front Med (Lausanne). 2022;9:1079323 (Dec 22). Doi: 10.3389/fmed.2022.1079323

Key clinical point: Children and adolescents with atopic dermatitis (AD) are at an increased risk of developing juvenile idiopathic arthritis (JIA).

Major finding: Patients with AD vs control individuals had an increased risk for JIA (adjusted odds ratio [aOR] 1.58; 95% CI 1.41-1.77), especially for psoriatic JIA (aOR 2.75; 95% CI 1.64-4.60).

Study details: This population-based register study included 70,584 patients with AD aged <18 years at the time of the first AD diagnosis and 270,783 age- and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators for or receiving educational grants, speaker honoraria, or consultation honoraria from various organizations.

Source: Keskitalo PL et al. Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study. J Am Acad Dermatol. 2023 (Jan 3). Doi: 10.1016/j.jaad.2022.12.025

Key clinical point: Children and adolescents with atopic dermatitis (AD) are at an increased risk of developing juvenile idiopathic arthritis (JIA).

Major finding: Patients with AD vs control individuals had an increased risk for JIA (adjusted odds ratio [aOR] 1.58; 95% CI 1.41-1.77), especially for psoriatic JIA (aOR 2.75; 95% CI 1.64-4.60).

Study details: This population-based register study included 70,584 patients with AD aged <18 years at the time of the first AD diagnosis and 270,783 age- and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators for or receiving educational grants, speaker honoraria, or consultation honoraria from various organizations.

Source: Keskitalo PL et al. Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study. J Am Acad Dermatol. 2023 (Jan 3). Doi: 10.1016/j.jaad.2022.12.025

Key clinical point: Children and adolescents with atopic dermatitis (AD) are at an increased risk of developing juvenile idiopathic arthritis (JIA).

Major finding: Patients with AD vs control individuals had an increased risk for JIA (adjusted odds ratio [aOR] 1.58; 95% CI 1.41-1.77), especially for psoriatic JIA (aOR 2.75; 95% CI 1.64-4.60).

Study details: This population-based register study included 70,584 patients with AD aged <18 years at the time of the first AD diagnosis and 270,783 age- and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators for or receiving educational grants, speaker honoraria, or consultation honoraria from various organizations.

Source: Keskitalo PL et al. Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study. J Am Acad Dermatol. 2023 (Jan 3). Doi: 10.1016/j.jaad.2022.12.025

Key clinical point: Treatment of patients with atopic dermatitis (AD) with dupilumab is not associated with the development of primary or recurrent malignancy.

Major finding: Dupilumab-exposed and unexposed patients had comparable incidence rates of primary malignancies (adjusted hazard ratio [aHR], 1.010; P  =  .946), keratinocyte cancers (aHR, 0.994; P  =  .973), and recurrent cancers (aHR, 0.828; P  =  .758) per 1,000 person-years.

Study details: This single-center 5-year retrospective study included 9,707 patients with AD, of which 1,627 patients received dupilumab treatment.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants for and/or receiving research funds from various organizations.

Source: Owji S et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022 (Dec 26). Doi: 10.1016/j.jaip.2022.12.018.

Key clinical point: Treatment of patients with atopic dermatitis (AD) with dupilumab is not associated with the development of primary or recurrent malignancy.

Major finding: Dupilumab-exposed and unexposed patients had comparable incidence rates of primary malignancies (adjusted hazard ratio [aHR], 1.010; P  =  .946), keratinocyte cancers (aHR, 0.994; P  =  .973), and recurrent cancers (aHR, 0.828; P  =  .758) per 1,000 person-years.

Study details: This single-center 5-year retrospective study included 9,707 patients with AD, of which 1,627 patients received dupilumab treatment.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants for and/or receiving research funds from various organizations.

Source: Owji S et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022 (Dec 26). Doi: 10.1016/j.jaip.2022.12.018.

Key clinical point: Treatment of patients with atopic dermatitis (AD) with dupilumab is not associated with the development of primary or recurrent malignancy.

Major finding: Dupilumab-exposed and unexposed patients had comparable incidence rates of primary malignancies (adjusted hazard ratio [aHR], 1.010; P  =  .946), keratinocyte cancers (aHR, 0.994; P  =  .973), and recurrent cancers (aHR, 0.828; P  =  .758) per 1,000 person-years.

Study details: This single-center 5-year retrospective study included 9,707 patients with AD, of which 1,627 patients received dupilumab treatment.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants for and/or receiving research funds from various organizations.

Source: Owji S et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022 (Dec 26). Doi: 10.1016/j.jaip.2022.12.018.

Key clinical point: Fatigue is a common symptom in children with atopic dermatitis (AD), particularly those with moderate-to-severe AD, and thus should be considered in clinical practice and trials.

Major finding: Most children had no (38.6%) or mild (32.1%) parent-proxy fatigue, but 27.2% had moderate fatigue and 2.0% had severe fatigue. Higher proportions of children with moderate-to-severe parent-proxy Patient-Reported Outcome Measurement Information System Pediatric fatigue scores were those with moderate (25.7%/1.4%) and severe (39.3%/5.4%) AD vs mild AD (18.0%/0.0%), as determined by Investigator’s Global Assessment, especially those with 5-6 (44.4%/0.0%) or 7 (44.2%/5.2%) nights of sleep disturbance from eczema.

Study details: This cross-sectional observational study included 248 children aged 0-17 years with AD.

Disclosures: This study was funded by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

Source: Rangel SM et al. Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Dec 21). Doi: 10.1111/jdv.18819

Key clinical point: Fatigue is a common symptom in children with atopic dermatitis (AD), particularly those with moderate-to-severe AD, and thus should be considered in clinical practice and trials.

Major finding: Most children had no (38.6%) or mild (32.1%) parent-proxy fatigue, but 27.2% had moderate fatigue and 2.0% had severe fatigue. Higher proportions of children with moderate-to-severe parent-proxy Patient-Reported Outcome Measurement Information System Pediatric fatigue scores were those with moderate (25.7%/1.4%) and severe (39.3%/5.4%) AD vs mild AD (18.0%/0.0%), as determined by Investigator’s Global Assessment, especially those with 5-6 (44.4%/0.0%) or 7 (44.2%/5.2%) nights of sleep disturbance from eczema.

Study details: This cross-sectional observational study included 248 children aged 0-17 years with AD.

Disclosures: This study was funded by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

Source: Rangel SM et al. Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Dec 21). Doi: 10.1111/jdv.18819

Key clinical point: Fatigue is a common symptom in children with atopic dermatitis (AD), particularly those with moderate-to-severe AD, and thus should be considered in clinical practice and trials.

Major finding: Most children had no (38.6%) or mild (32.1%) parent-proxy fatigue, but 27.2% had moderate fatigue and 2.0% had severe fatigue. Higher proportions of children with moderate-to-severe parent-proxy Patient-Reported Outcome Measurement Information System Pediatric fatigue scores were those with moderate (25.7%/1.4%) and severe (39.3%/5.4%) AD vs mild AD (18.0%/0.0%), as determined by Investigator’s Global Assessment, especially those with 5-6 (44.4%/0.0%) or 7 (44.2%/5.2%) nights of sleep disturbance from eczema.

Study details: This cross-sectional observational study included 248 children aged 0-17 years with AD.

Disclosures: This study was funded by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

Source: Rangel SM et al. Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Dec 21). Doi: 10.1111/jdv.18819

Key clinical point: Dupilumab maintained efficacy against moderate-to-severe atopic dermatitis (AD) with no new safety signals over 104 weeks; however, it was ineffective in treating head-and-neck AD.

Major finding: The median Eczema Area and Severity Index score decreased significantly from 18.0 at baseline to 2.0 at week 52 and 1.7 at week 104 (both P < .0001); 35% of patients reported an adverse event, with conjunctivitis being the most common (25%). Although the 104-week treatment persistence rate was 86%, the majority of patients still had AD in the head-and-neck area.

Study details: This real-world study included 347 adult patients with moderate-to-severe AD who received dupilumab and were registered in the prospective Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) registry during 2017-2022.

Disclosures: The SCRATCH registry was supported by research grants from Sanofi-Genzyme and Pfizer. Some authors reported ties with various organizations, including Sanofi-Genzyme and Pfizer.

Source: Vittrup I et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023 (Jan 6). Doi: 10.1111/jdv.18849

Key clinical point: Dupilumab maintained efficacy against moderate-to-severe atopic dermatitis (AD) with no new safety signals over 104 weeks; however, it was ineffective in treating head-and-neck AD.

Major finding: The median Eczema Area and Severity Index score decreased significantly from 18.0 at baseline to 2.0 at week 52 and 1.7 at week 104 (both P < .0001); 35% of patients reported an adverse event, with conjunctivitis being the most common (25%). Although the 104-week treatment persistence rate was 86%, the majority of patients still had AD in the head-and-neck area.

Study details: This real-world study included 347 adult patients with moderate-to-severe AD who received dupilumab and were registered in the prospective Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) registry during 2017-2022.

Disclosures: The SCRATCH registry was supported by research grants from Sanofi-Genzyme and Pfizer. Some authors reported ties with various organizations, including Sanofi-Genzyme and Pfizer.

Source: Vittrup I et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023 (Jan 6). Doi: 10.1111/jdv.18849

Key clinical point: Dupilumab maintained efficacy against moderate-to-severe atopic dermatitis (AD) with no new safety signals over 104 weeks; however, it was ineffective in treating head-and-neck AD.

Major finding: The median Eczema Area and Severity Index score decreased significantly from 18.0 at baseline to 2.0 at week 52 and 1.7 at week 104 (both P < .0001); 35% of patients reported an adverse event, with conjunctivitis being the most common (25%). Although the 104-week treatment persistence rate was 86%, the majority of patients still had AD in the head-and-neck area.

Study details: This real-world study included 347 adult patients with moderate-to-severe AD who received dupilumab and were registered in the prospective Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) registry during 2017-2022.

Disclosures: The SCRATCH registry was supported by research grants from Sanofi-Genzyme and Pfizer. Some authors reported ties with various organizations, including Sanofi-Genzyme and Pfizer.

Source: Vittrup I et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023 (Jan 6). Doi: 10.1111/jdv.18849

Key clinical point: Upadacitinib is effective and safe for the treatment of patients with difficult-to-treat moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, the percentages of patients achieving the Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 were 94.29%, 91.43%, 74.29%, and 60.0%, respectively; 91.43% of patients achieved a ≥4-point decrease in itch-numerical rating scale score. No severe adverse events were reported.

Study details: This single-center retrospective real-life study included 38 patients aged ≥12 years with moderate-to-severe AD and inadequate response, intolerance, or contraindications to cyclosporine or dupilumab who had received upadacitinib (15/30 mg daily) for ≥8 weeks; 35 patients received the treatment for 16 weeks.

Disclosures: This study was supported by grants from Fondazione Roma, Italian Ministry of Health (Rome, Italy), “Ricerca Finalizzata” project. Some authors reported ties with various organizations.

Source: Gargiulo L et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A single-center 16-week study. Dermatol Ther (Heidelb). 2023 (Jan 9). Doi: 10.1007/s13555-022-00882-z

Key clinical point: Upadacitinib is effective and safe for the treatment of patients with difficult-to-treat moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, the percentages of patients achieving the Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 were 94.29%, 91.43%, 74.29%, and 60.0%, respectively; 91.43% of patients achieved a ≥4-point decrease in itch-numerical rating scale score. No severe adverse events were reported.

Study details: This single-center retrospective real-life study included 38 patients aged ≥12 years with moderate-to-severe AD and inadequate response, intolerance, or contraindications to cyclosporine or dupilumab who had received upadacitinib (15/30 mg daily) for ≥8 weeks; 35 patients received the treatment for 16 weeks.

Disclosures: This study was supported by grants from Fondazione Roma, Italian Ministry of Health (Rome, Italy), “Ricerca Finalizzata” project. Some authors reported ties with various organizations.

Source: Gargiulo L et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A single-center 16-week study. Dermatol Ther (Heidelb). 2023 (Jan 9). Doi: 10.1007/s13555-022-00882-z

Key clinical point: Upadacitinib is effective and safe for the treatment of patients with difficult-to-treat moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, the percentages of patients achieving the Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 were 94.29%, 91.43%, 74.29%, and 60.0%, respectively; 91.43% of patients achieved a ≥4-point decrease in itch-numerical rating scale score. No severe adverse events were reported.

Study details: This single-center retrospective real-life study included 38 patients aged ≥12 years with moderate-to-severe AD and inadequate response, intolerance, or contraindications to cyclosporine or dupilumab who had received upadacitinib (15/30 mg daily) for ≥8 weeks; 35 patients received the treatment for 16 weeks.

Disclosures: This study was supported by grants from Fondazione Roma, Italian Ministry of Health (Rome, Italy), “Ricerca Finalizzata” project. Some authors reported ties with various organizations.

Source: Gargiulo L et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A single-center 16-week study. Dermatol Ther (Heidelb). 2023 (Jan 9). Doi: 10.1007/s13555-022-00882-z

Key clinical point: The safety profile of baricitinib in patients with moderate-to-severe atopic dermatitis (AD) was similar to that reported in earlier analyses; major adverse cardiovascular event (MACE), pulmonary embolism (PE), and malignancy were within the background range.

Major finding: The adjusted incidence rate/100 patient-years at risk for any infection was 67.2 and that for herpes simplex, herpes zoster, opportunistic infections, serious adverse events, MACE, PE, and 14 malignancies excluding nonmelanoma skin cancer was 6.7, 2.8, 0.3, 5.2, 0.15, 0.06, and 0.3, respectively.

Study details: This updated integrated analysis of eight clinical trials included 2636 patients with moderate-to-severe AD treated with ≥1 baricitinib dose (1/2/4 mg) through 3.9 years (4628.4 patient-years of exposure).

Disclosures: Baricitinib is developed by Eli Lilly and Company, under license from Incyte Corporation. Some authors reported ties with various organizations, including Eli Lilly. Five authors declared being employees and stockholders of Eli Lilly.

Source: Bieber T et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: An updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2022 (Dec 22). Doi: 10.1080/09546634.2022.2161812

Key clinical point: The safety profile of baricitinib in patients with moderate-to-severe atopic dermatitis (AD) was similar to that reported in earlier analyses; major adverse cardiovascular event (MACE), pulmonary embolism (PE), and malignancy were within the background range.

Major finding: The adjusted incidence rate/100 patient-years at risk for any infection was 67.2 and that for herpes simplex, herpes zoster, opportunistic infections, serious adverse events, MACE, PE, and 14 malignancies excluding nonmelanoma skin cancer was 6.7, 2.8, 0.3, 5.2, 0.15, 0.06, and 0.3, respectively.

Study details: This updated integrated analysis of eight clinical trials included 2636 patients with moderate-to-severe AD treated with ≥1 baricitinib dose (1/2/4 mg) through 3.9 years (4628.4 patient-years of exposure).

Disclosures: Baricitinib is developed by Eli Lilly and Company, under license from Incyte Corporation. Some authors reported ties with various organizations, including Eli Lilly. Five authors declared being employees and stockholders of Eli Lilly.

Source: Bieber T et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: An updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2022 (Dec 22). Doi: 10.1080/09546634.2022.2161812

Key clinical point: The safety profile of baricitinib in patients with moderate-to-severe atopic dermatitis (AD) was similar to that reported in earlier analyses; major adverse cardiovascular event (MACE), pulmonary embolism (PE), and malignancy were within the background range.

Major finding: The adjusted incidence rate/100 patient-years at risk for any infection was 67.2 and that for herpes simplex, herpes zoster, opportunistic infections, serious adverse events, MACE, PE, and 14 malignancies excluding nonmelanoma skin cancer was 6.7, 2.8, 0.3, 5.2, 0.15, 0.06, and 0.3, respectively.

Study details: This updated integrated analysis of eight clinical trials included 2636 patients with moderate-to-severe AD treated with ≥1 baricitinib dose (1/2/4 mg) through 3.9 years (4628.4 patient-years of exposure).

Disclosures: Baricitinib is developed by Eli Lilly and Company, under license from Incyte Corporation. Some authors reported ties with various organizations, including Eli Lilly. Five authors declared being employees and stockholders of Eli Lilly.

Source: Bieber T et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: An updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2022 (Dec 22). Doi: 10.1080/09546634.2022.2161812